Cargando…
Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment
INTRODUCTION: Hemangioblastomas are rare, histologically benign, highly vascularized tumors of the brain, the spinal cord, and the retina, occurring sporadically or associated with the autosomal dominant inherited von Hippel-Lindau (VHL) disease. Children or adults with VHL disease have one of >...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575510/ https://www.ncbi.nlm.nih.gov/pubmed/32507909 http://dx.doi.org/10.1007/s00381-020-04712-5 |
_version_ | 1783597824671219712 |
---|---|
author | Klingler, Jan-Helge Gläsker, Sven Bausch, Birke Urbach, Horst Krauss, Tobias Jilg, Cordula A. Steiert, Christine Puzik, Alexander Neumann-Haefelin, Elke Kotsis, Fruzsina Agostini, Hansjürgen Neumann, Hartmut P.H. Beck, Jürgen |
author_facet | Klingler, Jan-Helge Gläsker, Sven Bausch, Birke Urbach, Horst Krauss, Tobias Jilg, Cordula A. Steiert, Christine Puzik, Alexander Neumann-Haefelin, Elke Kotsis, Fruzsina Agostini, Hansjürgen Neumann, Hartmut P.H. Beck, Jürgen |
author_sort | Klingler, Jan-Helge |
collection | PubMed |
description | INTRODUCTION: Hemangioblastomas are rare, histologically benign, highly vascularized tumors of the brain, the spinal cord, and the retina, occurring sporadically or associated with the autosomal dominant inherited von Hippel-Lindau (VHL) disease. Children or adults with VHL disease have one of > 300 known germline mutations of the VHL gene located on chromosome 3. They are prone to develop hemangioblastomas, extremely rarely starting at age 6, rarely at age 12–18, and, typically and almost all, as adults. There is a plethora of VHL-associated tumors and cysts, mainly in the kidney, pancreas, adrenals, reproductive organs, and central nervous system. Due to a lack of causal treatment, alleviation of symptoms and prevention of permanent neurological deficits as well as malignant transformation are the main task. Paucity of data and the nonlinear course of tumor progression make management of pediatric VHL patients with hemangioblastomas challenging. METHODS: The Freiburg surveillance protocol was developed by combining data from the literature and our experience of examinations of > 300 VHL patients per year at our university VHL center. RESULTS: Key recommendations are to start screening of patients at risk by funduscopy with dilated pupils for retinal tumors with admission to school and with MRI of the brain and spinal cord at age 14, then continue biannually until age 18, with emergency MRI in case of neurological symptoms. Indication for surgery remains personalized and should be approved by an experienced VHL board, but we regard neurological symptoms, rapid tumor growth, or critically large tumor/cyst sizes as the key indications to remove hemangioblastomas. Since repeated surgery on hemangioblastomas in VHL patients is not rare, modern neurosurgical techniques should encompass microsurgery, neuronavigation, intraoperative neuromonitoring, fluorescein dye-based intraoperative angiography, intraoperative ultrasound, and minimally invasive approaches, preceded in selected cases by endovascular embolization. Highly specialized neurosurgeons are able to achieve a very low risk of permanent morbidity for the removal of hemangioblastomas from the cerebellum and spinal cord. Small retinal tumors of the peripheral retina can be treated by laser coagulation, larger tumors by cryocoagulation or brachytherapy. CONCLUSION: We consider management at experienced VHL centers mandatory and careful surveillance and monitoring of asymptomatic lesions are required to prevent unnecessary operations and minimize morbidity. |
format | Online Article Text |
id | pubmed-7575510 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-75755102020-10-21 Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment Klingler, Jan-Helge Gläsker, Sven Bausch, Birke Urbach, Horst Krauss, Tobias Jilg, Cordula A. Steiert, Christine Puzik, Alexander Neumann-Haefelin, Elke Kotsis, Fruzsina Agostini, Hansjürgen Neumann, Hartmut P.H. Beck, Jürgen Childs Nerv Syst Annual Issue Paper INTRODUCTION: Hemangioblastomas are rare, histologically benign, highly vascularized tumors of the brain, the spinal cord, and the retina, occurring sporadically or associated with the autosomal dominant inherited von Hippel-Lindau (VHL) disease. Children or adults with VHL disease have one of > 300 known germline mutations of the VHL gene located on chromosome 3. They are prone to develop hemangioblastomas, extremely rarely starting at age 6, rarely at age 12–18, and, typically and almost all, as adults. There is a plethora of VHL-associated tumors and cysts, mainly in the kidney, pancreas, adrenals, reproductive organs, and central nervous system. Due to a lack of causal treatment, alleviation of symptoms and prevention of permanent neurological deficits as well as malignant transformation are the main task. Paucity of data and the nonlinear course of tumor progression make management of pediatric VHL patients with hemangioblastomas challenging. METHODS: The Freiburg surveillance protocol was developed by combining data from the literature and our experience of examinations of > 300 VHL patients per year at our university VHL center. RESULTS: Key recommendations are to start screening of patients at risk by funduscopy with dilated pupils for retinal tumors with admission to school and with MRI of the brain and spinal cord at age 14, then continue biannually until age 18, with emergency MRI in case of neurological symptoms. Indication for surgery remains personalized and should be approved by an experienced VHL board, but we regard neurological symptoms, rapid tumor growth, or critically large tumor/cyst sizes as the key indications to remove hemangioblastomas. Since repeated surgery on hemangioblastomas in VHL patients is not rare, modern neurosurgical techniques should encompass microsurgery, neuronavigation, intraoperative neuromonitoring, fluorescein dye-based intraoperative angiography, intraoperative ultrasound, and minimally invasive approaches, preceded in selected cases by endovascular embolization. Highly specialized neurosurgeons are able to achieve a very low risk of permanent morbidity for the removal of hemangioblastomas from the cerebellum and spinal cord. Small retinal tumors of the peripheral retina can be treated by laser coagulation, larger tumors by cryocoagulation or brachytherapy. CONCLUSION: We consider management at experienced VHL centers mandatory and careful surveillance and monitoring of asymptomatic lesions are required to prevent unnecessary operations and minimize morbidity. Springer Berlin Heidelberg 2020-06-07 2020 /pmc/articles/PMC7575510/ /pubmed/32507909 http://dx.doi.org/10.1007/s00381-020-04712-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Annual Issue Paper Klingler, Jan-Helge Gläsker, Sven Bausch, Birke Urbach, Horst Krauss, Tobias Jilg, Cordula A. Steiert, Christine Puzik, Alexander Neumann-Haefelin, Elke Kotsis, Fruzsina Agostini, Hansjürgen Neumann, Hartmut P.H. Beck, Jürgen Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment |
title | Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment |
title_full | Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment |
title_fullStr | Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment |
title_full_unstemmed | Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment |
title_short | Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment |
title_sort | hemangioblastoma and von hippel-lindau disease: genetic background, spectrum of disease, and neurosurgical treatment |
topic | Annual Issue Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575510/ https://www.ncbi.nlm.nih.gov/pubmed/32507909 http://dx.doi.org/10.1007/s00381-020-04712-5 |
work_keys_str_mv | AT klinglerjanhelge hemangioblastomaandvonhippellindaudiseasegeneticbackgroundspectrumofdiseaseandneurosurgicaltreatment AT glaskersven hemangioblastomaandvonhippellindaudiseasegeneticbackgroundspectrumofdiseaseandneurosurgicaltreatment AT bauschbirke hemangioblastomaandvonhippellindaudiseasegeneticbackgroundspectrumofdiseaseandneurosurgicaltreatment AT urbachhorst hemangioblastomaandvonhippellindaudiseasegeneticbackgroundspectrumofdiseaseandneurosurgicaltreatment AT krausstobias hemangioblastomaandvonhippellindaudiseasegeneticbackgroundspectrumofdiseaseandneurosurgicaltreatment AT jilgcordulaa hemangioblastomaandvonhippellindaudiseasegeneticbackgroundspectrumofdiseaseandneurosurgicaltreatment AT steiertchristine hemangioblastomaandvonhippellindaudiseasegeneticbackgroundspectrumofdiseaseandneurosurgicaltreatment AT puzikalexander hemangioblastomaandvonhippellindaudiseasegeneticbackgroundspectrumofdiseaseandneurosurgicaltreatment AT neumannhaefelinelke hemangioblastomaandvonhippellindaudiseasegeneticbackgroundspectrumofdiseaseandneurosurgicaltreatment AT kotsisfruzsina hemangioblastomaandvonhippellindaudiseasegeneticbackgroundspectrumofdiseaseandneurosurgicaltreatment AT agostinihansjurgen hemangioblastomaandvonhippellindaudiseasegeneticbackgroundspectrumofdiseaseandneurosurgicaltreatment AT neumannhartmutph hemangioblastomaandvonhippellindaudiseasegeneticbackgroundspectrumofdiseaseandneurosurgicaltreatment AT beckjurgen hemangioblastomaandvonhippellindaudiseasegeneticbackgroundspectrumofdiseaseandneurosurgicaltreatment |